Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES Plunges 9%; BSE HEALTHCARE Index Down 0.5%
Wed, 30 Oct 9:56

VENUS REMEDIES Plunges 9%; BSE HEALTHCARE Index Down 0.5%Image source: Chunumunu/www.istockphoto.com

VENUS REMEDIES share price has plunged 9% and is presently trading at Rs 312.8.

Meanwhile, the BSE HEALTHCARE index is at 43,014.1 (down 0.5%).

Among the top losers in the BSE HEALTHCARE index today are Cipla (down 3.7%) and Torrent Pharma (down 2.6%).

POLY MEDICURE (up 4.1%) and FDC (up 1.9%) are among the top gainers today.

Over the last one year, VENUS REMEDIES has moved up from Rs 273.3 to Rs 312.8, registering a gain of Rs 39.5 (up 14.4%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,014.1, registering a gain of 57.1% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 185.5%), SUVEN PHARMACEUTICALS (up 125.7%) and Glenmark Pharma (up 123.3%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,029.1 (down 0.4%).

The top losers among the BSE Sensex today are ICICI Bank (down 1.6%) and Sun Pharma (down 1.6%). The most traded stocks in the BSE Sensex are Power Grid Corp. and Tata Motors.

In the meantime, NSE Nifty is at 24,416.6 (down 0.2%). Cipla and Dr. Reddys are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 80,029.1, registering a gain of 15,916.5 points (up 24.8%).

VENUS REMEDIES Financial Update...

VENUS REMEDIES net profit grew 3.4% YoY to Rs 12 million for the quarter ended June 2024, compared to a profit of Rs 12 million a year ago. Net sales rose 14.1% to Rs 1,086 million during the period as against Rs 952 million in April-June 2023.

For the year ended March 2024, VENUS REMEDIES reported 7.2% increase in net profit to Rs 285 million compared to net profit of Rs 266 million during FY23. Revenue of the company grew 8.3% to Rs 6,014 million during FY24.

The current Price to earnings ratio of VENUS REMEDIES, based on rolling 12 month earnings, stands at 14.7.


Equitymaster requests your view! Post a comment on "VENUS REMEDIES Plunges 9%; BSE HEALTHCARE Index Down 0.5%". Click here!